Skip to content

Palvella Therapeutics PVLA Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$73.46M+3.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$11.77M+53.3%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$159.56M-254%
Arrowhead Research logo
Arrowhead ResearchARWR
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Palvella Therapeutics (PVLA) reported comprehensive income (loss), net of tax, attributable to parent of -$15.76M in Q1 2026.
How has Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 92.3% year-over-year, from -$8.19M to -$15.76M.
What is the long-term trend for Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2021 to 2025), Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a -3.4% compound annual growth rate (CAGR), from -$44.61M to -$41.64M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This is a comprehensive measure of financial performance that includes both net income and other items that bypass the income statement, such as foreign currency translation adjustments. It provides a broader view of the total change in equity resulting from non-owner sources during a specific period. Investors use this to assess the total economic impact of all financial activities on shareholder value.